lung

12345678910111213141516171819
Across
  1. 1. the response restored by LIBTAYO
  2. 3. color of LIBTAYO
  3. 6. generates fully human therapeutic antibodies, including LIBTAYO
  4. 8. 360 mg infusion, every 3 weeks
  5. 11. first line immune response
  6. 12. criteria used to select patients for clinical trials
  7. 14. LIBTAYO______ enhances patient access to LIBTAYO
  8. 15. approves drug indications
  9. 17. immune function inhibited by LIBTAYO
  10. 18. number of approved FDA indications for LIBTAYO
  11. 19. action taken when a patient experiences a severe adverse reaction
Down
  1. 2. expresses programmed death receptor
  2. 4. tumor staging criteria
  3. 5. LIBTAYO biologic
  4. 7. objective response rate. Duration of response. Complete response rate. Safety and tolerability.
  5. 9. administration method of LIBTAYO
  6. 10. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  7. 13. method to confirm objective response rate (ORR)
  8. 14. profile in which adverse reactions are reported
  9. 16. organization of clinical trials